Eli Lilly and Company has announced plans to bolster its domestic medicine production by building four new pharmaceutical manufacturing sites in the US. This new investment brings the company’s total US capital expansion commitments to more than $50 billion since 2020. 

Three of the future US sites announced will focus on manufacturing active pharmaceutical ingredients (API), reshoring capabilities of small-molecule chemical synthesis, and further strengthening Lilly’s supply chain. The fourth location will extend the company’s global parenteral manufacturing network for future injectable therapies. The investments extend to products across therapeutic areas.  

At these four new sites, Lilly expects to create more than 3,000 jobs. Additionally, the company anticipates that it could create nearly 10,000 construction jobs during the development of the sites. 

The company’s previous total domestic capital expansion commitments from 2020 to 2024 totaled $23 billion and represented in today’s $50 billion announcement, included: 

• New sites in Research Triangle Park and Concord, North Carolina; 

• New sites at the LEAP Innovation District in Lebanon, Indiana; 

• Expansions and updates to several different manufacturing facilities in Indianapolis, Indiana;  

• Development of the new Lilly Medicine Foundry in Lebanon, Indiana; and  

• Acquisition and expansion of Lilly’s manufacturing site in Kenosha County, Wisconsin 

Source: Eli Lilly and Company